# US 2023/0068959 A1 · Branched multi-functional macromonomers and related polymers and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0068959 A1
- Document ID: US20230068959A1
- Status: Published application
- Kind: A1
- Application number: 17/751,540
- Filed: 2022-05-23
- Published: 2023-03-02
- Earliest claimed: 2017-06-30
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Jeremiah A. Johnson; Nolan Gallagher; Farrukh Vohidov; Yivan Jiang; Hung Vanthanh Nguyen
- Web page: https://patentgrep.com/patent/US20230068959A1

## CPC

- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61P 35/00: Antineoplastic agents
- B01J 31/2278: {Complexes comprising two carbene ligands differing from each other, e.g. Grubbs second generation catalysts}
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C08G 61/08: of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
- C08G 69/48: Polymers modified by chemical after-treatment
- C08G 83/00: Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08L 71/02: Polyalkylene oxides
- G01N 33/575: for cancer
- B01J 2523/821: Ruthenium
- C08G 2261/135: Cross-linked structures
- C08G 2261/136: Comb-like structures
- C08G 2261/1414: Unsaturated aliphatic units
- C08G 2261/1424: containing ether groups, including alkoxy
- C08G 2261/1426: containing carboxy groups (COOH) and/or -C(=O)O-moieties
- C08G 2261/1432: containing amide groups
- C08G 2261/418: Ring opening metathesis polymerisation [ROMP]
- C08G 2261/76: crosslinking
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed are methods, compositions, reagents, systems, and kits to prepare and utilize branched multi-functional macromonomers, which contain a ring-opening metathesis polymerizable norbornene group, one or more reactive sites capable of undergoing click chemistry, and a terminal acyl group capable of undergoing a coupling reaction; branched multi-cargo macromonomers; and the corresponding polymers are disclosed herein. Various embodiments show that the macromonomers and polymers disclosed herein display unprecedented control of cargo loading of agents. These materials have the potential to be utilized for the treatment of diseases and conditions such as cancer and hypertension.

## Claims

### Claim 1

A macromonomer of Formula (I):
or a salt thereof, wherein:
each instance of RA is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl;
a is an integer from 1 to 20, inclusive;
each instance of M is independently hydrogen or an agent;
each instance of m is independently an integer from 1 to 10, inclusive;
each instance of L is independently substituted or unsubstituted, C1-200 alkylene, substituted or unsubstituted, C2-200 alkenylene, substituted or unsubstituted, C2-200 alkynylene, substituted or unsubstituted, C2-200 heteroalkylene, substituted or unsubstituted, C2-200 heteroalkenylene, or substituted or unsubstituted, C2-200 heteroalkynylene, wherein:
optionally one or more carbons in each instance of the substituted or unsubstituted, C1-200 alkylene, substituted or unsubstituted, C2-200 alkenylene, substituted or unsubstituted, C2-200 alkynylene, substituted or unsubstituted, C2-200 heteroalkylene, substituted or unsubstituted, C2-200 heteroalkenylene, and substituted or unsubstituted, C2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
optionally one or more heteroatoms in each instance of the substituted or unsubstituted, C2-200 heteroalkylene, substituted or unsubstituted, C2-200 heteroalkenylene, and substituted or unsubstituted, C2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
provided that when each instance of M is hydrogen, at least one instance of -L(M)m comprises a click-chemistry handle;
each instance of RB is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl;
each instance of b is independently an integer from 1 to 20, inclusive;
e is an integer from 1 to 10, inclusive;
X is ORC or N(RD)2, wherein:
RC is hydrogen, substituted or unsubstituted, C1-1000 alkyl, substituted or unsubstituted, C2-1000 alkenyl, substituted or unsubstituted, C2-1000 alkynyl, substituted or unsubstituted, C1-1000 heteroalkyl, substituted or unsubstituted, C2-1000 heteroalkenyl, substituted or unsubstituted, C2-1000 heteroalkynyl, an oxygen protecting group, or a leaving group; and
each instance of RD is independently hydrogen, substituted or unsubstituted, C1-1000 alkyl, substituted or unsubstituted, C2-1000 alkenyl, substituted or unsubstituted, C2-1000 alkynyl, substituted or unsubstituted, C1-1000 heteroalkyl, substituted or unsubstituted, C2-1000 heteroalkenyl, substituted or unsubstituted, C2-1000 heteroalkynyl, two RD are taken together to form a substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl moiety, or a nitrogen protecting group.

### Claim 2

A macromonomer of Formula (II):
or a salt thereof, wherein:
each instance of RA is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl;
a is an integer from 1 to 20, inclusive;
each instance of M′ is independently an agent;
each instance of m′ is independently an integer from 2 to 10, inclusive;
each instance of L is independently substituted or unsubstituted, C1-200 alkylene, substituted or unsubstituted, C2-200 alkenylene, substituted or unsubstituted, C2-200 alkynylene, substituted or unsubstituted, C2-200 heteroalkylene, substituted or unsubstituted, C2-200 heteroalkenylene, or substituted or unsubstituted, C2-200 heteroalkynylene, wherein:
optionally one or more carbons in each instance of the substituted or unsubstituted, C1-200 alkylene, substituted or unsubstituted, C2-200 alkenylene, substituted or unsubstituted, C2-200 alkynylene, substituted or unsubstituted, C2-200 heteroalkylene, substituted or unsubstituted, C2-200 heteroalkenylene, and substituted or unsubstituted, C2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
optionally one or more heteroatoms in each instance of the substituted or unsubstituted, C2-200 heteroalkylene, substituted or unsubstituted, C2-200 heteroalkenylene, and substituted or unsubstituted, C2-200 heteroalkynylene are independently replaced with substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
each instance of RB is independently hydrogen, halogen, or substituted or unsubstituted, C1-6 alkyl;
each instance of b is independently an integer from 1 to 20, inclusive;
e is an integer from 1 to 10, inclusive;
X is ORC or N(RD)2, wherein:
RC is hydrogen, substituted or unsubstituted, C1-1000 alkyl, substituted or unsubstituted, C2-1000 alkenyl, substituted or unsubstituted, C2-1000 alkynyl, substituted or unsubstituted, C1-1000 heteroalkyl, substituted or unsubstituted, C2-1000 heteroalkenyl, substituted or unsubstituted, C2-1000 heteroalkynyl, an oxygen protecting group, or a leaving group;
each instance of RD is independently hydrogen, substituted or unsubstituted, C1-1000 alkyl, substituted or unsubstituted, C2-1000 alkenyl, substituted or unsubstituted, C2-1000 alkynyl, substituted or unsubstituted, C1-1000 heteroalkyl, substituted or unsubstituted, C2-1000 heteroalkenyl, substituted or unsubstituted, C2-1000 heteroalkynyl, two RD are taken together to form a substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl moiety, or a nitrogen protecting group; and
each instance of R1 is independently hydrogen, halogen, substituted or unsubstituted, C1-6 alkyl, or two R1 bonded to the same carbon are taken together to form an oxo group.

### Claim 3

A compound of Formula (III):
or a salt thereof, wherein:
each instance of L1 is independently substituted or unsubstituted, C1-20 alkylene, or substituted or unsubstituted, C2-20 heteroalkylene;
X1 is O or NRI, wherein:
RI is independently hydrogen, substituted or unsubstituted, C1-10 alkyl, substituted or unsubstituted, C2-10 alkenyl, substituted or unsubstituted, C1-10 heteroalkyl, substituted or unsubstituted, C2-10 heteroalkenyl, or a nitrogen protecting group;
W, Y, and Z are each independently hydrogen, substituted or unsubstituted, C1-100 alkylene, substituted or unsubstituted, C2-100 heteroalkylene, or a group of formula (i), provided that at least one instance of W, Y, or Z is a group of formula (i),
wherein formula (i) is:

### Claim at position 4

4-127. (canceled)

### Claim 128 (depends on 1)

A method of preparing a macromonomer of claim 1, or a salt thereof, comprising coupling a compound of the formula:
or a salt thereof, with a compound of the formula: HORC or HN(RD)2, or a salt thereof.

### Claim 129 (depends on 2)

A method of preparing a macromonomer of claim 2, or a salt thereof, comprising coupling a compound of the formula:
or a salt thereof, with a compound of the formula: HORC or HN(RD)2, or a salt thereof.

### Claim at position 7

130-131. (canceled)

### Claim 132 (depends on 2)

A method of preparing a macromonomer of claim 2, comprising coupling a compound of the formula:
or salt thereof, with a compound of Formula (III) to provide a macromonomer of Formula (II).

### Claim 133 (depends on 2)

A polymer prepared by polymerizing a macromonomer of claim 2, or a salt thereof, in the presence of a metathesis catalyst.

### Claim at position 10

134-141. (canceled)

### Claim 142 (depends on 2)

A method of preparing a polymer comprising polymerizing a macromonomer of claim 2, or a salt thereof, in the presence of a metathesis catalyst.

### Claim 143

(canceled)

### Claim 144 (depends on 133)

A pharmaceutical composition comprising a polymer claim 133 and optionally a pharmaceutically acceptable excipient, wherein at least one instance of M or M′ is a therapeutic agent, a diagnostic agent, or a prophylactic agent.

### Claim 145 (depends on 133)

A kit comprising:
a polymer of claim 133; and
instructions for using the polymer.

### Claim 146 (depends on 133)

A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a subject comprising administering to the subject a polymer of claim 133, wherein at least one instance of M or M′ is a therapeutic agent, a diagnostic agent, or a prophylactic agent.

### Claim 147 (depends on 133)

A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a cell comprising contacting the cell with a polymer of claim 133, wherein at least one instance of M or M′ is a therapeutic agent, a diagnostic agent, or a prophylactic agent.

### Claim at position 17

148-149. (canceled)

### Claim 150 (depends on 133)

A method of treating a disease or condition in a subject in need thereof comprising administering to or implanting in the subject in need thereof a therapeutically effective amount of:
a polymer of claim 133;
wherein at least one instance of M or M′ is a therapeutic agent.

### Claim 151 (depends on 133)

A method of preventing a disease or condition in a subject in need thereof comprising administering to or implanting in the subject in need thereof a prophylactically effective amount of
a polymer of claim 133;
wherein at least one instance of M or M′ is a prophylactic agent.

### Claim 152 (depends on 133)

A method of diagnosing a disease or condition in a subject comprising administering to or implanting in the subject a diagnostically effective amount of
a polymer of claim 133;
wherein at least one instance of M or M′ is a diagnostic agent.

### Claim at position 21

153-156. (canceled)

### Claim 157 (depends on 1)

A polymer prepared by polymerizing a macromonomer of claim 1, or a salt thereof, in the presence of a metathesis catalyst.

### Claim 158 (depends on 1)

A method of preparing a polymer comprising polymerizing a macromonomer of claim 1, or a salt thereof, in the presence of a metathesis catalyst.

### Claim 159 (depends on 157)

A pharmaceutical composition comprising a polymer of claim 157 and optionally a pharmaceutically acceptable excipient, wherein at least one instance of M or M′ is a therapeutic agent, a diagnostic agent, or a prophylactic agent.

### Claim 160 (depends on 157)

A kit comprising:
a polymer of claim 157; and
instructions for using the polymer.

### Claim 161 (depends on 157)

A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a subject comprising administering to the subject a polymer of claim 157, wherein at least one instance of M or M′ is a therapeutic agent, a diagnostic agent, or a prophylactic agent.

### Claim 162 (depends on 157)

A method of delivering a therapeutic agent, a diagnostic agent, or a prophylactic agent to a cell comprising contacting the cell with a polymer of claim 157, wherein at least one instance of M or M′ is a therapeutic agent, a diagnostic agent, or a prophylactic agent.

### Claim 163 (depends on 157)

A method of treating a disease or condition in a subject in need thereof comprising administering to or implanting in the subject in need thereof a therapeutically effective amount of a polymer of claim 157; wherein at least one instance of M or M′ is a therapeutic agent.

### Claim 164 (depends on 157)

A method of preventing a disease or condition in a subject in need thereof comprising administering to or implanting in the subject in need thereof a prophylactically effective amount of a polymer of claim 157; wherein at least one instance of M or M′ is a prophylactic agent.

### Claim 165 (depends on 157)

A method of diagnosing a disease or condition in a subject comprising administering to or implanting in the subject a diagnostically effective amount of a polymer of claim 157; wherein at least one instance of M or M′ is a diagnostic agent.
